| 摘要 |
A novel dihydrate crystal of 3-Ä4-(8-fluoro-5,11-dihydrobenzÄbÜoxepinoÄ4,3-bÜpyridin-11-ylidene)pip eridinoÜpropionic acid providing high-intensity diffraction peaks at diffraction angles (2&thetas;) of about 4.2 DEG , 17.0 DEG , and 21.3 DEG in a powder X-ray diffraction profile; a medicament comprising said dihydrate crystal; and a process for preparing said dihydrate crystal which comprises the steps of treating a crystalline substance containing an anhydride crystal of the above compound with hydrous acetone, and subjecting the product to drying treatment and moistening treatment. |
